Mycobacterium avium subsp. paratuberculosis
Mycobacterium avium subsp. paratuberculosis (MAP) is a subspecies of the bacterium Mycobacterium avium, known to cause Johne's disease (pronounced "Yo-knee's disease") in cattle and has been suspected of being a causative agent in human Crohn's disease. MAP is an acid-fast bacterium that is hardy and can survive in harsh environmental conditions for extended periods. It is of significant concern in veterinary medicine, agriculture, and potentially human health.
Characteristics[edit]
MAP is a small, rod-shaped, non-motile bacterium. It is difficult to culture in the laboratory due to its slow growth rate and specific nutritional requirements. The bacterium is characterized by its thick, waxy cell wall, which not only contributes to its durability in the environment but also its resistance to chemical disinfectants and antibiotics. This cell wall is also responsible for its acid-fast properties, making it visible under a microscope with special staining techniques such as the Ziehl-Neelsen stain.
Transmission[edit]
The primary route of transmission of MAP is fecal-oral. In cattle, it is shed in high numbers in the feces of infected animals and can contaminate soil, water, and feed, leading to the infection of other members of the herd. Calves are particularly susceptible to infection but may not show symptoms until they reach adulthood, making control and eradication efforts challenging. There is also concern about the potential for MAP to be transmitted to humans through the consumption of contaminated milk and meat products, although the link to human disease remains controversial.
Disease in Animals[edit]
MAP causes Johne's disease, a chronic enteritis that affects the intestines of ruminants such as cattle, sheep, and goats. Infected animals suffer from weight loss, diarrhea, and reduced milk production, which can lead to significant economic losses in the agricultural sector. There is no cure for Johne's disease, and control measures focus on preventing infection through improved hygiene, culling infected animals, and vaccination.
Potential Link to Crohn's Disease[edit]
There has been ongoing debate within the scientific community about the role of MAP in Crohn's disease, a chronic inflammatory bowel disease in humans. Some studies have detected the presence of MAP in tissue samples from patients with Crohn's disease at higher rates than in the general population. However, a direct causal relationship has not been conclusively established, and research in this area continues.
Diagnosis and Control[edit]
Diagnosis of MAP infection in animals is challenging due to the bacterium's slow growth rate and the late onset of clinical symptoms. Tests such as culture, PCR (polymerase chain reaction), and ELISA (enzyme-linked immunosorbent assay) are used to detect the presence of the bacterium or antibodies against it. Control measures in livestock populations include testing and culling of infected animals, improving sanitation, and vaccination.
Conclusion[edit]
Mycobacterium avium subsp. paratuberculosis is a significant pathogen in veterinary medicine with potential implications for human health. Its resilience in the environment and resistance to treatment pose considerable challenges for control and eradication efforts. Ongoing research into its role in Crohn's disease highlights the need for a better understanding of zoonotic diseases and the interactions between animal and human health.
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian